Australia's most trusted
source of pharma news
Posted 27 October 2021 PM
With generics subsidiary Sandoz dragging on the performance of Novartis the pharmaceutical giant is again looking at shedding the division, undertaking a "strategic review" into which options maximise value.
In its third quarter results Novartis reported net sales growing five per cent year-on-year in constant currency. Its Innovative Medicines division grew seven per cent, but the generics division Sandoz declined two per cent due to ongoing pricing pressures.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.